Silica xerogels as pharmaceutical drug carriers

Synthesis of pure and doped nano-calcium phosphates using different conventional methods for biomedical applications: a review

The applications of calcium phosphates (hydroxyapatite, tetracalcium phosphate, tricalcium phosphate (alpha and beta), fluorapatite, di-calcium phosphate anhydrous, and amorphous calcium-phosphate) are increasing day by day. Calcium hydroxyapatite, commonly known as hydroxyapatite (HAp), represents a mineral form of calcium apatite. Owing to its close molecular resemblance to the mineral constituents of bones, teeth, and hard tissues, HAp is often employed in the biomedical domain. In addition, it is extensively employed in various sectors such as the remediation of water, air, and soil pollution. The key advantage of HAp lies in its potential to accommodate a wide variety of anionic and cationic substitutions. Nevertheless, HAp and tricalcium phosphate (TCP) syntheses typically involve the use of chemical precursors containing calcium and phosphorus sources and employ diverse techniques, such as solid-state, wet, and thermal methods or a combination of these processes. Researchers are increasingly favoring natural sources such as bio-waste (eggshells, oyster shells, animal bones, fish scales, etc.) as viable options for synthesizing HAp. Interestingly, the synthesis route significantly influences the morphology, size, and crystalline phase of calcium phosphates. In this review paper, we highlight both dry and wet methods, which include six commonly used synthesis methods (i.e. solid-state, mechano-chemical, wet-chemical precipitation, hydrolysis, sol-gel, and hydrothermal methods) coupled with the variation in source materials and their influence in modifying the structural morphology from a bulky state to nanoscale to explore the applications of multifunctional calcium phosphates in different formats.

Silica-Cyclodextrin Hybrid Materials: Two Possible Synthesis Processes

Both cyclodextrin (CD) and porous silica possess interesting properties of adsorption and release. A silica-CD hybrid, therefore, could synergically merge the properties of the two components, giving rise to a material with appealing properties for both environmental and pharmaceutical applications. With this aim, in the present study, a first hybrid is obtained through one-pot sol-gel synthesis starting from CD and tetramethyl orthosilicate (TMOS) as a silica precursor. In particular, methyl-β-cyclodextrin (bMCD) is selected for this purpose. The obtained bMCD-silica hybrid is a dense material containing a considerable amount of bMCD (45 wt.%) in amorphous form and therefore represents a promising support. However, since a high specific surface area is desirable to increase the release/adsorption properties, an attempt is made to produce the hybrid material in the form of an aerogel. Both the synthesis of the gel and its drying in supercritical CO2 are optimized in order to reach this goal. All the obtained samples are characterized in terms of their physico-chemical properties (infra-red spectroscopy, thermogravimetry) and structure (X-ray diffraction, electron microscopy) in order to investigate their composition and the interaction between the organic component (bMCD) and the inorganic one (silica).

Silane coatings modified with hydroxyapatite nanoparticles to enhance the biocompatibility and corrosion resistance of a magnesium alloy

The fast corrosion rate of magnesium alloys has restricted their use as biodegradable implants. Hence developing a practical approach to retard the corrosion rate of the AZ31 magnesium alloy, as well as promoting cell adhesion and proliferation is of great importance. Silane coatings were applied through dip coating, on samples pretreated in hydrofluoric acid. Samples were immersed in simulated body fluid at 37 °C, and the coating performance was assessed by electrochemical impedance spectroscopy. The coating morphologies of samples were investigated through field emission scanning electron microscopy and a cell viability/proliferation (MTT) test was performed to evaluate cellular response. A 2.2 μm-thick coating was accomplished, which increased the corrosion resistance to three orders of magnitude higher than that of the bare sample. Hydroxyapatite nanoparticles were added to the silane coating to improve biocompatibility and facilitate bone formation. Changing the concentration of hydroxyapatite nanoparticles not only helped to optimize the barrier properties of the silane coating but also ameliorated MG-63 osteoblastic cell growth. The findings showed great promise to enhance and maintain the corrosion barrier property and induce high osteoblastic differentiation by employing 1000 mg L⁻¹ of hydroxyapatite nanoparticles.

Incorporation of hydroxyapatite nanoparticles in silane coatings improves both corrosion resistance and cell viability on magnesium AZ31 implants.

Antibacterial Activity of Linezolid against Gram-Negative Bacteria: Utilization of ε-Poly-l-Lysine Capped Silica Xerogel as an Activating Carrier

In recent times, many approaches have been developed against drug resistant Gram-negative bacteria. However, low-cost high effective materials which could broaden the spectrum of antibiotics are still needed. In this study, enhancement of linezolid spectrum, normally active against Gram-positive bacteria, was aimed for Gram-negative bacteria growth inhibition. For this purpose, a silica xerogel prepared from a low-cost precursor is used as a drug carrier owing to the advantages of its mesoporous structure, suitable pore and particle size and ultralow density. The silica xerogel is loaded with linezolid and capped with ε-poly-l-lysine. The developed nano-formulation shows a marked antibacterial activity against to Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus. In comparison to free linezolid and ε-poly-l-lysine, the material demonstrates a synergistic effect on killing for the three tested bacteria. The results show that silica xerogels can be used as a potential drug carrier and activity enhancer. This strategy could provide the improvement of antibacterial activity spectrum of antibacterial agents like linezolid and could represent a powerful alternative to overcome antibiotic resistance in a near future.

Determination of the fate and biological responses of food additive silica particles in commercial foods

Synthetic amorphous silica (SAS) is widely added to commercial foods as an anticaking agent. Concern about the potential application of nanosized silica in foods has increased as nanomaterials are not intended for use as food additives. This study evaluated the particle size distributions and biological responses of food additive SAS. An accurate, sensitive, and cost-effective analytical method for probing SAS was established, and quantitative analysis of its presence in commercial foods was performed. The results demonstrate that food additive SAS is an aggregated material composed of nanosized particles with nanosized aggregates of silica particles identified in commercial foods. Food additive SAS did not exhibit acute cytotoxicity compared to both general-grade nano (G-nano) and bulk (G-bulk) silica. Moreover, intestinal transport amounts of food additive SAS were significantly lower than for G-nano. Taken together, we find that food additive SAS does not exhibit acute toxicity resulting from nanosized materials.

Novel degradation flow-through chamber for in vitro biomaterial characterization

The characterization of degradation of biodegradable materials for tissue regeneration is classically carried out in three steps: in vitro degradation analysis, in vitro cell culture, and in vivo animal experiments. Each step involves an increasing complexity and should serve a more sophisticated material selection, which serves as an orientation to clinical studies and the final application in patients. Recently, the usefulness of degradation analyses is being discussed. In this context, the aim of this work is to increase the importance of in vitro degradation analysis by using flowing media to move closer to the in vivo situation. In the long term, this should lead to a more sensitive biomaterial characterization as well as to a replacement of time-consuming static or quasi-dynamic incubation experiments. The practicability of the novel chamber is demonstrated in context of a degradation study of silica/collagen/calcium phosphate composites in flowing media with physiological (2.4 mM) and lowered (0.5 mM) calcium ion concentrations. This is done by comparison with static and quasi-dynamic incubation experiments. In order to keep all media regimes comparable to each other, for the dynamic experiment, a flow rate was chosen equivalent to the medium exchange in quasi-dynamic incubation. Under flow-through conditions, there is a clearly decreased tendency to lower the calcium concentration, so that a concentration close to the physiological initial situation can be continuously maintained.

Drug Release as a function of bioactivity, incubation regime, liquid, and initial load: Release of bortezomib from calcium phosphate-containing silica/collagen xerogels

The ability of silica-/collagen-based composite xerogels to act as drug delivery systems was evaluated by taking into account the initial drug concentration, bioactivity of the xerogels, liquid, and incubation regime. The proteasome inhibitor bortezomib was chosen as a model drug, used for the systemic treatment of multiple myeloma. Incubation during 14 days in phosphate-buffered saline (PBS) or simulated body fluid (SBF) showed a weak initial burst and was identified to be of first order with subsequent release being independent from the initial load of 0.1 or 0.2 mg bortezomib per 60 mg monolithic sample. Faster drug release occurred during incubation in SBF compared to PBS, and during static incubation without changing the liquid, compared to dynamic incubation with daily liquid changes. Drug-loaded xerogels with hydroxyapatite as a third component exhibited enhanced bioactivity retarding drug release, explained by formation of a surface calcium phosphate layer. The fastest release of 50% of the total drug load was observed for biphasic xerogels after 7 days during dynamic incubation in SBF. As a result, the presented concept is suitable for the intended combination of the advantageous bone substitution properties of xerogels and local application of drugs exemplified by bortezomib. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 106B: 1165-1173, 2018.

A nano silver-xerogel (Ag nps@modified TEOS) as a newly developed nanocatalyst in the synthesis of benzopyranopyrimidines (with secondary and primary amines) and gem-bisamides

Silver nanoparticles have been prepared from a chemical reduction approach and supported on modified TEOS (tetraethylorthosilicate) xerogel to be studied as a nanocatalyst.

An Overview of Therapeutic Applications

Over the last few years' great advances have been made on the development drug delivery systems for different purposes for targeting the diseased conditions. Novel drug delivery originates from polymers or associated with some devices is generally related with the emergence of novel characteristics. These changes are what eventually comprise the value of drug delivery system and Novel drug delivery system. Novel properties become existed without making new materials. Novel drug delivery system comparable to traditional system, following Targeted Drug Delivery System (TDDS) is also called targeting drug system. A new drug delivery system makes the drugs densely gather pathological-change structures, and has an improved healing effect and less toxic side effects. The drugs can improve the strength of pharmacological action and reduce the bad effect all over the body, for they release in the target organs.

The accelerating effect of chitosan-silica hybrid dressing materials on the early phase of wound healing

Commercialized dressing materials with or without silver have played a passive role in early-phase wound healing, protecting the skin defects from infections, absorbing exudate, and preventing dehydration. Chitosan (CTS)-based sponges have been developed in pure or hybrid forms for accelerating wound healing, but their wound-healing capabilities have not been extensively compared with widely used commercial dressing materials, providing limited information in a practical aspect. In this study, we have developed CTS-silica (CTS-Si) hybrid sponges with water absorption, flexibility, and mechanical behavior similar to those of CTS sponges. In vitro and in vivo tests were performed to compare the CTS-Si sponges with three commercial dressing materials [gauze, polyurethane (PU), and silver-containing hydrofiber (HF-Ag)] in addition to CTS sponges. Both in vitro and in vivo tests showed that CTS-Si sponges promoted fibroblast proliferation, leading to accelerated collagen synthesis, whereas the CTS sponges did not exhibit significant differences in fibroblast proliferation and collagen synthesis from gauze, PU, and HF-Ag sponges. In case of CTS-Si, the inflammatory cells were actively recruited to the wound by the influence of the released silicon ions from CTS-Si sponges, which, in return, led to an enhanced secretion of growth factors, particularly TGF-β during the early stage. The higher level of TGF-β likely improved the proliferation of fibroblasts, and as a result, collagen synthesis by fibroblasts became remarkably productive, thereby increasing collagen density at the wound site. Therefore, the CTS-Si hybrid sponges have considerable potential as a wound-dressing material for accelerating wound healing. © 2016 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 105B: 1828-1839, 2017.

Intracranial biodegradable silica-based nimodipine drug release implant for treating vasospasm in subarachnoid hemorrhage in an experimental healthy pig and dog model

Nimodipine is a widely used medication for treating delayed cerebral ischemia (DCI) after subarachnoid hemorrhage. When administrated orally or intravenously, systemic hypotension is an undesirable side effect. Intracranial subarachnoid delivery of nimodipine during aneurysm clipping may be more efficient way of preventing vasospasm and DCI due to higher concentration of nimodipine in cerebrospinal fluid (CSF). The risk of systemic hypotension may also be decreased with intracranial delivery. We used animal models to evaluate the feasibility of surgically implanting a silica-based nimodipine releasing implant into the subarachnoid space through a frontotemporal craniotomy. Concentrations of released nimodipine were measured from plasma samples and CSF samples. Implant degradation was followed using CT imaging. After completing the recovery period, full histological examination was performed on the brain and meninges. The in vitro characteristics of the implant were determined. Our results show that the biodegradable silica-based implant can be used for an intracranial drug delivery system and no major histopathological foreign body reactions were observed. CT imaging is a feasible method for determining the degradation of silica implants in vivo. The sustained release profiles of nimodipine in CSF were achieved. Compared to a traditional treatment, higher nimodipine CSF/plasma ratios can be obtained with the implant.

The design and synthesis of a soluble composite silica xerogel and the short-time release of proteins

The controlled release of large molecules (such as proteins) in a very short time (several days) was achieved through the co-hydrolysis and co-condensation of different precursors.

Multi-arm PEG/silica hydrogel for sustained ocular drug delivery

In the present study, a series of sustained drug delivery multiarm poly(ethylene glycol) (PEG)/silica hydrogels were prepared and characterized. The hydrogels were formed by hydrolysis and condensation of poly(4-arm PEG silicate) using the sol-gel method. The relationships between water content in the PEG/silica hydrogel and stability as well as rheological properties were evaluated. Scanning electron microscopy analysis of the PEG/silica hydrogels revealed water content-dependent changes in microstructure. An increase in water content resulted in larger pores within the hydrogel, longer gelation time and higher viscosity. The PEG/silica hydrogels were loaded with dexamethasone (DMS) or dexamethasone sodium phosphate (DMSP), drugs that are hydrophobic and hydrophilic in nature, respectively. Evaluation of in vitro release revealed a zero-order release profile for DMS over the first 6 days, suggesting that degradation of the silica hydrogel matrix was the primary mechanism of drug release. It was also found that the drug-release profile could be tailored by varying the water content used during hydrogel preparation. In contrast, more than 90% of DMSP was released within 1 h, suggesting that DMSP release was only controlled by diffusion. Overall, results from this study indicate that PEG/silica hydrogels may be promising drug-eluting depot materials for the sustained delivery of hydrophobic, ophthalmic drugs.

Ordered nanoporous silica as carriers for improved delivery of water insoluble drugs: a comparative study between three dimensional and two dimensional macroporous silica

The goal of the present study was to compare the drug release properties and stability of the nanoporous silica with different pore architectures as a matrix for improved delivery of poorly soluble drugs. For this purpose, three dimensional ordered macroporous (3DOM) silica with 3D continuous and interconnected macropores of different sizes (200 nm and 500 nm) and classic mesoporous silica (ie, Mobil Composition of Matter [MCM]-41 and Santa Barbara Amorphous [SBA]-15) with well-ordered two dimensional (2D) cylindrical mesopores were successfully fabricated and then loaded with the model drug indomethacin (IMC) via the solvent deposition method. Scanning electron microscopy (SEM), N₂ adsorption, differential scanning calorimetry (DSC), and X-ray diffraction (XRD) were applied to systematically characterize all IMC-loaded nanoporous silica formulations, evidencing the successful inclusion of IMC into nanopores, the reduced crystallinity, and finally accelerated dissolution of IMC. It was worth mentioning that, in comparison to 2D mesoporous silica, 3DOM silica displayed a more rapid release profile, which may be ascribed to the 3D interconnected pore networks and the highly accessible surface areas. The results obtained from the stability test indicated that the amorphous state of IMC entrapped in the 2D mesoporous silica (SBA-15 and MCM-41) has a better physical stability than in that of 3DOM silica. Moreover, the dissolution rate and stability of IMC loaded in 3DOM silica was closely related to the pore size of macroporous silica. The colorimetric 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and Cell Counting Kit (CCK)-8 assays in combination with direct morphology observations demonstrated the good biocompatibility of nanoporous silica, especially for 3DOM silica and SBA-15. The present work encourages further study of the drug release properties and stability of drug entrapped in different pore architecture of silica in order to realize their potential in oral drug delivery.

Nitric oxide-releasing xerogels synthesized from N-diazeniumdiolate-modified silane precursors

Nitric oxide (NO)-releasing xerogel materials were synthesized using N-diazeniumdiolate-modified silane monomers that were subsequently co-condensed with an alkoxysilane. The NO-release characteristics were tuned by varying the aminosilane structure and concentration. The resulting materials exhibited maximum NO release totals and durations ranging from 0.45-3.2 μmol cm(-2) and 20-90 h, respectively. The stability of the xerogel networks was optimized by varying the alkoxysilane backbone identity, water to silane ratio, base catalyst concentration, reaction time, and drying conditions. The response of glucose biosensors prepared using the NO-releasing xerogel (15 mol % N-diazeniumdiolate-modified N-2-(aminoethyl)-aminopropyltrimethoxysilane) as an outer sensor membrane was linear (R(2) = 0.979) up to 24 mM glucose. The sensitivity (3.4 nA mM(-1)) of the device to glucose was maintained for 7 days in phosphate buffered saline. The facile sol-gel synthetic route, along with the NO release and glucose biosensor characteristics, demonstrates the versatility of this method for biosensor membrane applications.

Nonporous Silica Nanoparticles for Nanomedicine Application

Nanomedicine, the use of nanotechnology for biomedical applications, has potential to change the landscape of the diagnosis and therapy of many diseases. In the past several decades, the advancement in nanotechnology and material science has resulted in a large number of organic and inorganic nanomedicine platforms. Silica nanoparticles (NPs), which exhibit many unique properties, offer a promising drug delivery platform to realize the potential of nanomedicine. Mesoporous silica NPs have been extensively reviewed previously. Here we review the current state of the development and application of nonporous silica NPs for drug delivery and molecular imaging.

Controlled release of small molecules from silica xerogel with limited nanoporosity

Conventional sol-gel processing requires several distinct steps involving hydrolysis, condensation and drying to obtain a highly porous, glassy solid material. With the goal of achieving controlled release of small molecules, herein we focus on the acceleration of the condensation and drying steps by casting the hydrolyzed sol on a large open surface to achieve a denser 100 % silica xerogel structure. Thus, cast xerogel with a more limited porosity was prepared. The effect of synthesis parameters during sol-gel synthesis on the release kinetics of bupivacaine, vancomycin and cephalexin was investigated. The release kinetics fitted well with the Higuchi model, suggesting a diffusional release mechanism. Combining the release and nanostructure data, the formation mechanism of cast xerogel is described. Without introducing additional precursors or additives into sol-gel systems, sol-gel casting is an easy technique that further expands the applicability of sol-gel materials as excellent carriers for the controlled release of a variety of drugs.

Advancement in stimuli triggered in situ gelling delivery for local and systemic route

INTRODUCTION

Current research efforts focused on the design and evaluation of drug delivery systems that are easy to administer require decreased administration frequency, and provide sustained drug release in order to increase clinical efficacy and compliance of the patients. The gel forming smart polymeric formulations offer numerous applications resemble sustained and prolonged action in contrast to conventional drug delivery systems.

AREAS COVERED

Article summarizes type of bioactive, sol-gel triggering factors, dose, rationales, and polymers involved in gelation with respect to their route of administration. A lot of work has been done with smart polymeric gelling system taking the advantage of stimuli (temperature and pH) triggered sol-gel phase-transition in the administered area that have great prospective in biomedical and pharmaceutical applications, particularly in target-specific controlled drug delivery systems.

EXPERT OPINION

Although the principle of gelation is so attractive, key issues remain to be solved which include (i) variability of the drug release, (ii) avoidance of burst release in case of depot formulation, and (iii) issues related to toxicity. Unfortunately, till now area concerning the detailed processes of the gelling formation is still not much explored. Despite this proclamation, many efforts are made in industry and institutions to improve concerned approaches. New materials and approaches enter the preclinical and clinical phases and one can be sure that this strategy will gain further clinical importance within the next years. Thus, this review article will assuredly serve as an informative tool for the innovators working in the concern area.

Progress of oncolytic viruses in sarcomas

Oncolytic virotherapy has shown exciting promise for the treatment of many types of solid tumors. Pediatric sarcomas are an aggressive type of pediatric malignancy known to show limited responsiveness to current therapies, leading to unacceptably high morbidity and mortality. Oncolytic viruses have only recently been used for the treatment of this challenging cancer, and results have been encouraging. Five clinical trials are currently open evaluating the use of oncolytic viruses in pediatric malignancies. Advances in genetic engineering of the viruses include improving the ability of the virus to infect tumor cells, engineering the virus with transgenes which improve the virus' ability to kill tumor cells and manipulating the virus to enhance concomitantly administered therapies. Further understanding of the antiviral immune response and a viral induced anti-tumor immune response will permit a maximization of oncolytic virotherapy.

Drug nano-domains in spray-dried ibuprofen-silica microspheres

Silica microspheres encapsulating ibuprofen in separated domains at the nanometre scale are formed by spray-drying and sol-gel processes. A detailed (1)H and (13)C NMR study of these microspheres shows that ibuprofen molecules are mobile and are interacting through hydrogen bonds with other ibuprofen molecules. (1)H magnetisation exchange NMR experiments were employed to characterize the size of the ibuprofen domains at the nanometre scale. These domains are solely formed by ibuprofen, and their diameters are estimated to be ∼40 nm in agreement with TEM observations. The nature and formation of these particular texture and drug dispersion are discussed.

Silica xerogels and hydroxyapatite nanocrystals for the local delivery of platinum-bisphosphonate complexes in the treatment of bone tumors: a mini-review

The present review focuses on the "drug targeting and delivery" approach of the selective transportation of cisplatin to bone tumors and bone metastases. This aim is realized by binding cisplatin to (bis)phosphonate ligands or their derivatives. Geminal bisphosphonates are in clinical use in the treatment of several bone-related diseases because of their high affinity for calcium ions and hence for bones. Platinum-bisphosphonate complexes may be easily loaded onto calcium-containing inorganic matrices, such as calcium-doped sol-gel derived silica xerogels and hydroxyapatite nanocrystals, for local administration at the site of the bone malignancy. The composites may be used as bone-filler materials that, in addition to their action as bone substitutes, can also act as controlled platinum-drug releasing agents. The release kinetics of the drug can be tailored for specific therapeutic applications modulating the physico-chemical features of the inorganic matrices. Moreover, apatite nanocrystals loaded with platinum-bisphosphonate prodrugs can be used as injectable material for nanomedical applications (e.g. intracellular drug delivery).

Cyclodextrin-based nanogels for pharmaceutical and biomedical applications

Hydrophilic nanogels combine the advantages of hydrogels with certain advantages that are inherent in their nanoscale size. Similar to macrogels, nanogels can contain and protect drugs and regulate their release by incorporating high-affinity functional groups, stimuli-responsive conformations and biodegradable bonds into the polymer network. Similar to nanoparticles, nanogels can easily be administered in liquid form for parenteral drug delivery. The nanoscale size of nanogels gives them a high specific surface area that is available for further bioconjugation of active targeting agents. Biodistribution and drug release can be modulated through size adjustments. The incorporation of hydrophilic cyclodextrin (CD) moieties into the polymeric network of the nanogels provides them with a drug loading and release mechanism that is based on the formation of inclusion complexes without decreasing the hydrophilicity of the network. The covalent attachment of CD molecules to the chemically crosslinked networks may enable the CDs to display fully their ability to form complexes, while simultaneously preventing drug release upon media dilution. The preparation, characterization and advantages for pharmaceutical and biomedical applications of CD-based nanogels are reviewed in this article.

Bioactive silica-based drug delivery systems containing doxorubicin hydrochloride: in vitro studies

This study reports the applicability of sol-gel derived silica and silica-polydimethylsiloxane (silica-PDMS) composites as a potential bioactive implantable drug delivery system for doxorubicin hydrochloride (DOX). These composites also contain calcium chloride (CaCl(2)) and triethylphosphate as precursors of Ca(2+) and (PO(4))(3-) ions. These composites were immersed for 20 days in a simulated body fluid (SBF) at 37°C to study the release rate of the DOX, dissolution of the silica and the formation of hydroxyapatite on the composites' surface. The results show that the release rate of the DOX can be effectively tailored by either the addition of a polydimethylsiloxane (PDMS), or by varying the amount of CaCl(2), where the elution rate of DOX increases with increasing amount of the CaCl(2) precursor. Importantly, irrespective of the amount of CaCl(2), no burst release of DOX has been observed in any of the silica-PDMS system investigated. On the other hand, a slow release of DOX has been observed with a trend that followed a zero (0)-order kinetics for a total of 20 days of elusion. The dissolution of silica in SBF was ca. two-times faster than that of silica-PDMS, with the former reaching an average saturation level of 80 μg/mL whilst the latter reached 46 μg/mL within 20 days. Both the silica and the silica-PDMS composites show bioactivity i.e. they absorb calcium phosphate from SBF. Within 10 days, a ten-fold increase in the concentration of calcium phosphate deposit has been observed on the silica-PDMS relative to the silica. The constant rates of DOX release observed for the silica-PDMS composites indicate that the calcium phosphate deposit do not obstruct controlled release of the drug.

Effects of capsid-modified oncolytic adenoviruses and their combinations with gemcitabine or silica gel on pancreatic cancer

Conventional cancer treatments often have little impact on the course of advanced pancreatic cancer. Although cancer gene therapy with adenoviruses is a promising developmental approach, the primary receptor is poorly expressed in pancreatic cancers which might compromise efficacy and thus targeting to other receptors could be beneficial. Extended stealth delivery, combination with standard chemotherapy or circumvention of host antiadenoviral immune response might improve efficacy further. In this work, capsid-modified adenoviruses were studied for transduction of cell lines and clinical normal and tumor tissue samples. The respective oncolytic viruses were tested for oncolytic activity in vitro and in vivo. Survival was studied in a peritoneally disseminated pancreas cancer model, with or without concurrent gemcitabine while silica implants were utilized for extended intraperitoneal virus delivery. Immunocompetent mice and Syrian hamsters were used to study the effect of silica mediated delivery on antiviral immune responses and subsequent in vivo gene delivery. Capsid modifications selectively enhanced gene transfer to malignant pancreatic cancer cell lines and clinical samples. The respective oncolytic viruses resulted in increased cell killing in vitro, which translated into a survival benefit in mice. Early proinfammatory cytokine responses and formation of antiviral neutralizing antibodies was partially avoided with silica implants. The implant also shielded the virus from pre-existing neutralizing antibodies, while increasing the pancreas/liver gene delivery ratio six-fold. In conclusion, capsid modified adenoviruses would be useful for testing in pancreatic cancer trials. Silica implants might increase the safety and efficacy of the approach.

Oncolytic adenovirus research and applications

Cancer treatments have improved steadily, but still only few metastatic solid tumors can be cured. Apoptosis-resistant clones frequently develop following standard treatments. Resistance factors are shared between different treatment regimens and, therefore, loss of response can occur rapidly, despite changing the drug, and there is a tendency for crossresistance between modalities. Therefore, new agents with novel mechanisms of action are desperately needed. Oncolytic adenoviruses, featuring cancer-selective cell lysis and spread, constitute an interesting drug platform aimed towards the goals of tumor specificity, and have been engineered in a variety of ways to improve their selectivity and efficacy. They allow rational drug development by the genetic incorporation of targeting mechanisms that can exert their function at different stages of the viral replication cycle. Owing to their immunogenicity, adenoviruses are particularly attractive for immunostimulatory purposes.